GILD

Gilead Sciences
D

GILD

103.660
USD
0.42
(0.41%)
مغلق
حجم التداول
284,489
الربح لكل سهم
8
العائد الربحي
3.0
P/E
273
حجم السوق
129,056,700,000
الأفكار والتحليلات
هشام منسي
هشام منسي
منذ 6 أشهر
buy
2024-10-30 10:50
GILD Chart
المزيد
أصول ذات صلة
ABBV
ABBV
5.160
(2.67%)
198.440 USD
AMGN
AMGN
-2.15
(-0.76%)
281.20 USD
BIIB
BIIB
2.500
(2.07%)
123.460 USD
INCY
INCY
0.500
(0.81%)
62.500 USD
MRK
MRK
-0.090
(-0.11%)
83.160 USD
NVS
NVS
3.000
(2.69%)
114.320 USD
PFE
PFE
0.065
(0.27%)
24.185 USD
REGN
REGN
15.98
(2.71%)
606.12 USD
SNY
SNY
1.360
(2.51%)
55.470 USD
المزيد
الأخبار المقالات

العنوان: Gilead Sciences

القطاع: Healthcare
الصناعة: Drug Manufacturers - General
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).